Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen

Blood (2023) 142 (Supplement 1): 6735.

https://doi.org/10.1182/blood-2023-181444

Published: 2023

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan Schönland, Heather J Landau, Kwok Fiona, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Dasha Cherepanov, Vanessa C Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2021-148689

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Meletios A. Dimopoulos, S. Vincent Rajkumar, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Gareth J. Morgan, Arun Kumar, Kaveri Suryanarayan, Alexander Vorog, Andrew Fergus, Richard Labotka

Blood (2021) 138 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2021-150476

Published: 2021

Journal Articles

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi-Ankrah, Arun Kumar, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar

Blood (2021) 138 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2021-147838

Published: 2021

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos

Blood (2016) 128 (22): 3327.

https://doi.org/10.1182/blood.V128.22.3327.3327

Published: 2016

Journal Articles

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Neeraj Gupta, PhD, Michael J Hanley, PhD, Karthik Venkatakrishnan, PhD, Raymond Perez, MD, Robin E Norris, MD, John Nemunaitis, MD, Huyuan Yang, PhD, Gerald Falchook, MD, Richard Labotka, MD MS, Siqing Fu, MD PhD

Blood (2015) 126 (23): 3032.

https://doi.org/10.1182/blood.V126.23.3032.3032

Published: 2015

Journal Articles

Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD

Blood (2015) 126 (23): 3309.

https://doi.org/10.1182/blood.V126.23.3309.3309

Published: 2015

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD

Blood (2015) 126 (23): 4515.

https://doi.org/10.1182/blood.V126.23.4515.4515

Published: 2015

Journal Articles

Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Brian Seal, RPh, MBA, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD

Blood (2015) 126 (23): 4516.

https://doi.org/10.1182/blood.V126.23.4516.4516

Published: 2015

Journal Articles

Imaging of the diffusion of single band 3 molecules on normal and mutant erythrocytes

Gayani C. Kodippili, Jeff Spector, Caitlin Sullivan, Frans A. Kuypers, Richard Labotka, Patrick G. Gallagher, Ken Ritchie, Philip S. Low

Blood (2009) 113 (24): 6237–6245.

https://doi.org/10.1182/blood-2009-02-205450

Published: 2009

Includes: Supplemental data

Journal Articles

Evaluation of the Spectrin Compartment Size in Normal and Diseased Red Blood Cells by Single Particle Tracking.

Gayani C. Kodippili, MSc, Jeff Spector, MSc, Caitlin Sullivan, Richard Labotka, MD, Ken Ritchie, PhD, Philip S. Low, PhD

Blood (2007) 110 (11): 143.

https://doi.org/10.1182/blood.V110.11.143.143

Published: 2007

NARROW

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care

Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Imaging of the diffusion of single band 3 molecules on normal and mutant erythrocytes

Evaluation of the Spectrin Compartment Size in Normal and Diseased Red Blood Cells by Single Particle Tracking.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only